Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome: Epidemiology and Outcome of Neuronal Antibody Testing in Sweden

Table 1

Crude and age-adjusted incidence rates of AE and PNS in Healthcare region Mid Sweden 2015-2019.

Subgroup and time period	Crude incidence (CI95%)^†	Age-adjusted incidence (CI95%)^‡
AE + PNS 2015-2019	3.0 (1.9-4.1)	2.9 (1.8-3.8)
AE + PNS 2015	1.5 (0.0-3.2)	1.4 (0.0-2.9)
AE + PNS 2016	2.4 (0.30-4.6)	2.2 (0.027-4.2)
AE + PNS 2017	2.9 (0.58-5.2)	2.5 (0.30-4.6)
AE + PNS 2018	3.8 (1.2-6.5)	3.8 (1.2-6.5)
AE + PNS 2019	4.3 (1.5-7.1)	3.8 (1.3-6.3)
AE 2015-2019^§	2.4 (1.5-3.4)	2.4 (1.4-3.2)
PNS 2015-2019	1.5 (0.72-2.2)	1.3 (0.66-2.0)
Anti-NMDAR encephalitis 2015-2019	0.58 (0.12-1.1)	0.58 (0.12-1.0)
Anti-LGI1 encephalitis 2015-2019	0.58 (0.12-1.1)	0.53 (0.11-0.95)

^†Crude incidence rate per million person-years. ^‡Age-adjusted incidence rates per million person-years standardized to the 2013 European Standard population. ^§AE: definite AE and definite anti-NMDA receptor encephalitis. The population of Healthcare region Mid Sweden contributed with 10,331,778 person-years between 2015 and 2019. AE: autoimmune encephalitis; PNS: paraneoplastic neurological syndrome.